ArticleInternational endodontic journal2026
Novel Midkine-Derived Peptide Promotes Reparative Dentine Formation via DDIT4/mTOR Pathway-Mediated Activation of Autophagy.
Article in International endodontic journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimMidkine (MK) protein plays a critical regulatory role in tooth development and odontogenic differentiation, and has been shown to significantly promote reparative dentine formation. However, the direct application of recombinant MK protein as a pulp capping material presents clinical challenges and may increase medical costs. In contrast, peptides offer a cost-effective and feasible alternative by overcoming many of the limitations associated with full-length proteins. This study aimed to develop a novel MK-derived peptide for use in vital pulp therapy (VPT). METHODOLOGY: The human MK protein sequence was appropriately cleaved, resulting in the generation of multiple MK-derived peptides. The peptide with the highest mineralisation potential was identified through quantitative polymerase chain reaction (qPCR) and alizarin red S (ARS) staining. Cell proliferation, live/dead cell staining and apoptosis assays were conducted to evaluate the in vitro biosafety of MK-derived peptide. The optimal concentration of MK-derived peptide for promoting cell migration and odontogenic differentiation was determined using cell migration assays, qPCR, Western blotting, alkaline phosphatase staining and ARS staining. RNA sequencing, bioinformatics analysis, transmission electron microscopy and siRNA were used to explore the potential mechanism by which MK-derived peptide promotes odontogenesis. A rat pulp capping model was established, and in vivo evaluation was conducted through Micro-CT, H&E, Masson and immunohistochemical staining.
resultsFollowing appropriate cleavage of the human MK protein, a total of 15 peptides were generated, among which MK-12 (KARYNAQCQETI) exhibited the highest mineralisation potential. MK-12 demonstrated favourable in vitro biocompatibility at concentrations below 200 μg/mL, with the optimal effect on promoting cell migration and odontogenic differentiation observed at 100 μg/mL. RNA-sequencing and functional analyses revealed that MK-12 was closely associated with autophagy and mammalian target of rapamycin (mTOR) signalling pathways. Subsequent experiments demonstrated that MK-12 modulates the mTOR pathway and autophagy by upregulating the expression of DNA damage-inducible transcript 4 (DDIT4). In vivo studies confirmed that MK-12 effectively promoted the formation of reparative dentine and exhibited favourable biocompatibility.
conclusionMK-12, a peptide derived from midkine, was found to promote reparative dentine formation via DDIT4/mTOR pathway-mediated activation of autophagy, thereby providing a mechanistic basis for its potential clinical application in VPT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.